Seems it was not random which is a minus, but
>The combination of hydroxychloroquine + azithromycin was reserved for selected patients with severe COVID-19 and with minimal cardiac risk factors.
This group still saw improvement over no treatment, which is a huge plus(unless cardiac function is correlated with covid susceptibility).